CSL settles US lawsuit

Group secures deal including $US64m payment, profit outlook unchanged.

CSL (CSL) has reached a $US64 million settlement regarding a United States antitrust class action filed by US and Puerto Rican hospital groups.

In a statement to the Australian Securities Exchange, CSL said the settlement, which ends proceedings that have been ongoing since 2009, dismisses all claims and potential claims of class members against CSL in the lawsuit, as well as those against the Plasma Protein Therapeutics Association.

The settlement and $64 million sum are subject to approval in the US Federal Court and is expected to take several months.

Meanwhile, the group says the settlement will not change its expectation for net profit after tax (NPAT) growth from the guidance it provided during its full-year results in August.

"If approved, the settlement represents a one-off charge reducing NPAT expectations for fiscal 2014 by $US39 million, the group said

"This charge takes anticipated NPAT growth for the current financial year to approximately seven per cent, at 2012/2013 exchange rates."

CSL's chief executive officer Paul Perreault said the group continued to "strongly reject any allegation of wrong doing," but the settlement was in the best interests of the company and shareholders.

"To pursue the case further would have required several more years of management time and focus as well as substantial additional legal costs with no absolute certainty of the outcome," he said.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles